{"task_id": "7c720b34bc3d574f", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 266/464)", "text": "es (interval)\nAntibiotics (cont\u2019d)\nAntibiotics\n255\n\n--- Page 277 ---\nGENTAMICIN AND TOBRAMYCIN DOSING\nTOXICITY\nnephrotoxicity, ototoxicity, neuromuscu\nlar blockade (rare). Serum aminoglycoside levels cor\nrelate with nephrotoxicity\nLOADING DOSE (TRADITIONAL DOSING: Q8H)\ndependent\non\nindication.\nFor\nmild\ninfection,\nuncomplicated UTI, synergy with b lactams for\nGram positive infections, give 0.6 1.2 mg/kg IV\nq8h. For serious Gram positive infection or sepsis,\ngive 2.5 mg/kg IV. For life threatening infections,\ngive 3.0 mg/kg IV\nMAINTENANCE DOSE (TRADITIONAL DOSING:\nQ8H)\n\u0002\nSTART\n1.7 mg/kg IV q8h. Monitor serum levels\nafter steady state reached; i.e. 3 5 half lives (after\nthird dose). Monitor renal function and ototoxicity\nevery 3 days\n\u0002\nPEAK LEVELS\nobtain 30 45 min after end of infu\nsion. Should be 4.2 8.4 mmol/L [2 4 mg/mL] when\ndrug is being given for synergy or uncomplicated\ninfections, 12.6 16.8 mmol/L [6 8 mg/mL] for ser\nious Gram negative infection or sepsis, and\n14.7 18.9 mmol/L [7 9 mg/mL] for life threatening\ninfections\n\u0002\nTROUGH LEVELS\nobtain 0 30 min prior to sched\nuled dose. Should be <4.2 mmol/L [<2 mg/mL] to\nprevent toxicity\n\u0002\nADJUSTMENTS\ndosing interval is dependent on\nrenal function (CrCl >60 mL/min, q8h; 40 60 mL/\nmin, q12h; 20 40 mL/min, q24h; <20 mL/min\nsingle dose then measure serum concentration\nand give PRN). Changes in dose without changes\nin interval will result in proportional changes in\nboth peak and trough serum drug concentrations.\nProlongation of dosing interval will also reduce\nboth, but particularly trough level\nONCE DAILY GENTAMICIN AND TOBRAMYCIN\nDOSING\nRATIONALE\noptimize treatment of Gram negative\ninfections with less nephrotoxicity than q8h dosing.\nSimilar ototoxicity and neuromuscular toxicity\nNOT RECOMMENDED\nmonotherapy for infections\noutside urinary tract, pregnant patients, dialysis\npatients, endocarditis, CNS infections, osteomyelitis,\nophthalmologic\ninfections,\nsurgical\nprophylaxis,\npatients with rapid drug clearance (e.g. burns\n>20% BSA), Gram positive infections, patients receiv\ning concurrent ototoxins (e.g. furosemide) neonates,\npediatric patients with significant renal dysfunction,\nduration of therapy >14 days\nLOADING DOSE\n5 7 mg/kg IV\nMAINTENANCE DOSE (5 7 mg/kg IV q24 48h)\n\u0002\nSTART\nmonitor serum level 6 14h after first dose.\nMonitor renal function and ototoxicity q3d\nONCE DAILY GENTAMICIN AND TOBRAMYCIN\nDOSING (CONT\u2019D)\n\u0002\nADJUSTMENTS\ndosing interval (q24 48h) is based\non 6 14 h serum level (Hartford nomogram,\nAntimicrob Agents Chemother 1995 39:3).\nPharmacy consult to assist with dosing (Once\ndaily\ndosing\nprovides\npeak\nlevels\nof\n15 31 46 mmol/L [22 mg/mL] and trough levels\n<2.1 mmol/L [<1 mg/mL] to prevent toxicity. Peak\nand trough levels do not need to be monitored)\nDOSING WEIGHT FOR AMINOGLYCOSIDES\nfor\nobese patient (i.e. actual body weight (BW) >125%\nof ideal body weight (IBW)), use adjusted body\nweight (ABW) for dose determination:\n\u0002 ABW (kg)=IBW +0.4(BW IBW)\nNote: 1 kg=2.2 lbs. See p. 406 for IBW calculation\nRelated Topic\nDrug Eruptions (p. 372)\nVANCOMYCIN TOXICITY AND DOSING\nTOXICITY\nrash, infusion related red man syn\ndrome, rarely nephrotoxicity (especially combined\nwith aminoglycoside), and ototoxicity. However,\nserum vancomycin levels do not predict toxicity\nLOADING DOSE\n15 20 mg/kg (usually 1 1.5 g) IV\nMAINTENANCE DOSE\n30 mg/kg (actual body\nweight) per day divided into 2 4 doses (maximum\nusually 1.5 g/dose)\n\u0002\nSTART\nmonitoring after steady state, i.e. after\nthird dose normally, or after second dose if dosing\ninterval >48 hour. Monitor only if >14 days in\npatients with stable renal function and mild/mod\nerate infection, or >4 days in patients with\nunstable renal function or severe infection\n\u0002\nTROUGH LEVELS\nobtained 30 60 min before next\nscheduled dose. Should be at least 6.9 10.4 mmol/\nL [10 15 mg/mL]; adjust to 10.4 13.8 mmol/L\n[15 20 mg/mL] for serious infections (endocarditis,\nosteomyelitis)\n\u0002\nPEAK LEVELS\nthere is no correlate for efficacy or\ntoxicity and therefore should not be monitored\n\u0002\nADJUSTMENTS\ndosing interval is dependent on\nrenal\nfunction\n(CrCl\n>100\nmL/min,\nq12h;\n80 100 mL/min, q18h; 60 80 mL/min, q24h;\n40 60 mL/min, q36h; 25 40 mL/min q48h;\n<25 mL/min, single dose then measure serum\nconcentration and give PRN). Changes in dose\nwithout changes in interval will result in propor\ntional changes in both peak and trough serum\ndrug concentrations. Prolongation of dosing inter\nval will also reduce both, particularly trough level\n256\nAntibiotics", "text_length": 4481, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 266/464)", "type": "chunk", "chunk_index": 265, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.612767", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.613651", "status": "complete", "chunks_added": 3}